Where Will Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Go Next After It Is Up 1.06% in a Week?

Overall market sentiment has been down on Sonnet BioTherapeutics Holdings, Inc. (SONN) stock lately. SONN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sonnet BioTherapeutics Holdings, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SONN!

See Full SONN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With SONN Stock Today?

Sonnet BioTherapeutics Holdings, Inc. (SONN) stock is up 3.24% while the S&P 500 is lower by -0.63% as of 10:08 AM on Monday, Mar 11. SONN has risen $0.06 from the previous closing price of $1.85 on volume of 2,311,806 shares. Over the past year the S&P 500 has risen 32.04% while SONN is lower by -86.18%. SONN lost -$12.91 per share in the over the last 12 months.

More About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Click Here to get the full Stock Report for Sonnet BioTherapeutics Holdings, Inc. stock.